Apogee Therapeutics, Inc.

Welcome to the Apogee Therapeutics Conference call. At this time, all participants are in listen-only mode. There will be question and answer session after the prepared remarks. Please be advised that this call is being recorded at the company's request. I will now turn the call over to Noel Kurdi, Vice President of Investment Relations at Apogee. Noel, you may begin.

Thank you, operator, and thank you all for joining us today.

During this call, we will be making forward-looking statements related to our current expectations and plans for the company, as well as our clinical and preclinical programs. These statements represent our views as of this date and should not be relied upon as representing our views as of any subsequent date in the future. Looking at our agenda today, CEO Michael Henderson will begin the call with an introduction to today's results and the opportunity in atopic dermatitis. Then, Chief Medical Officer Carl Dambkowski will walk us through the APEX Part A 52-week maintenance results of Zumilocobar in patients with moderate to severe atopic dermatitis. Dr. Ruthann Flakels of Brigham and Women's Hospital and Harvard Medical School will then share an update on the unmet need in atopic dermatitis, followed by an overview of our Zumi Locavart development program by Christine O'Grallis Apigee's Head of Clinical Development and Medical Affairs. Before moving on to the Q&A, Michael will summarize our vision for building a leading I&I company and our anticipated milestones through the end of the year. The subsequent Q&A will be led by Michael, Carl, Apigee CFO Jane Pritchett Henderson, Chief Commercial Officer Jeff Hartness, and Dr. Blagels. I will now turn the call over to Michael.